CMA 100
Alternative Names: CMA-100Latest Information Update: 22 Feb 2023
At a glance
- Originator Life Biosciences
- Class Antidementias; Small molecules
- Mechanism of Action Autophagy stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Neurodegenerative disorders
Most Recent Events
- 22 Feb 2023 Discontinued - Preclinical for Alzheimer's disease in USA (PO) (Life Biosciences pipeline, February 2023)
- 22 Feb 2023 Discontinued - Preclinical for Neurodegenerative disorders in USA (PO) (Life Biosciences pipeline, February 2023)
- 29 Nov 2021 Preclinical trials in Alzheimer's disease in USA (PO) prior to November 2021